ADMA Biologics, Inc. P/E Ratio 2011–2025
ADMA Biologics, Inc. reported 30.40 of price-to-earnings ratio for fiscal 2025. That was 43.6% higher than fiscal 2024. Compared with fiscal 2024, the change was +43.6%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 30.40 | +43.6% |
| FY 2024 | 21.17 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
Source: ADMA Biologics, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ADMA 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ADMA Biologics, Inc. reported 30.40 of price-to-earnings ratio for fiscal 2025. That was 43.6% higher than fiscal 2024. Compared with fiscal 2024, the change was +43.6%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ADMA Biologics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeADMA Biologics, Inc. — frequently asked questions
What is ADMA Biologics, Inc.'s price-to-earnings ratio?
ADMA Biologics, Inc. (ADMA) reported price-to-earnings ratio of 30.40 for fiscal year 2025, per its SEC filings.
How has ADMA Biologics, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2011 and 2025, ADMA's price-to-earnings ratio grew at roughly 2.6% per year (compound annual rate), from 21.17 to 30.40.
Where does this data come from?
Figures are computed from ADMA Biologics, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More ADMA financial history
Full ADMA fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →